Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
ImmuPharma ( (GB:IMM) ) has shared an update.
ImmuPharma PLC announced an equity fundraise of approximately £2.91 million through an oversubscribed placing and a subscription agreement with Lanstead Capital Investors L.P. The funds are earmarked for further investment into the P140 technology, strengthening the company’s balance sheet, and covering general working capital and associated expenses. This move is part of ImmuPharma’s strategy to enhance its negotiating position in ongoing licensing discussions and drive positive share price momentum. The company aims to leverage advancements in its P140 platform for autoimmune diseases, expecting 2025 to be transformational with potential licensing deals and positive developments.
More about ImmuPharma
ImmuPharma PLC is a specialist drug discovery and development company focusing on innovative solutions within the pharmaceutical industry. The company is involved in the development of products targeting auto-immunity and anti-infectives, with a notable focus on its P140 autoimmune technology platform.
YTD Price Performance: 291.67%
Average Trading Volume: 9,365,586
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £20.07M
See more insights into IMM stock on TipRanks’ Stock Analysis page.
